|
Amolimogene
|
DB04904 |
[Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV). Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia.] |
|
Pagoclone
|
DB04903 |
[Pagoclone is an anxiolytic drug from the cyclopyrrolone family, which is related to other more well known drugs such as the sleeping medication zopiclone. It is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures.] |
|
Galiximab
|
DB04901 |
[Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.] |
|
Thymalfasin
|
DB04900 |
[Thymalfasin is a chemically synthesized version of thymosin alpha 1 that is identical to human thymosin alpha 1. Thymosin alpha 1 is an acetylated polypeptide. Thymosin alpha 1 is now approved in 35 developing countries for the treatment of Hepatitis B and C. It is also used to boost the immune response in the treatment of other diseases.] |
|
Pyridoxal-5'-Phosphate-N-Oxide
|
DB03629 |
|
|
Verpasep caltespen
|
DB04959 |
[HspE7 is a recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from _Mycobacterium bovis_, and the human papilloma viral (HPV) protein E7. Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers. E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes. It is being developed by StressGen Biotechnologies Corp.] |
|
Adamantane
|
DB03627 |
[A tricyclo bridged hydrocarbon. [PubChem]] |
|
ISO24
|
DB03628 |
|
|
Epratuzumab
|
DB04958 |
[Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.] |
|
Azimilide
|
DB04957 |
[Azimilide is an investigational class III anti-arrhythmic drug that blocks fast and slow components of the delayed rectifier cardiac potassium channels. It is not approved for use in any country, but is currently in clinical trials in the United States.] |
|
5-Methoxy-1,2-Dimethyl-3-(Phenoxymethyl)Indole-4,7-Dione
|
DB03626 |
|
|
Afelimomab
|
DB04956 |
[Afelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.] |
|
Pumactant
|
DB04955 |
[Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).] |
|
9-(4-Hydroxyphenyl)-2,7-Phenanthroline
|
DB03623 |
|
|
7-(Carboxyamino)-8-Amino-Nonanoic Acid
|
DB03624 |
|
|
Tecadenoson
|
DB04954 |
[Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. It is being developed by CV Therapeutics, Inc.] |
|
Ezogabine
|
DB04953 |
[Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine.] |
|
L-709,587
|
DB03621 |
|
|
5-[4-(2-Hydroxyethyl)-1-piperidinyl]-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione
|
DB03622 |
|
|
Ramoplanin
|
DB04952 |
[Ramoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD.] |
